Journal
AMERICAN JOURNAL OF HEMATOLOGY
Volume 92, Issue 2, Pages 161-170Publisher
WILEY-BLACKWELL
DOI: 10.1002/ajh.24615
Keywords
-
Categories
Funding
- Sanofi
- Seattle Genetics
- Spectrum
- Teva
- Celegene
- Merck
- Millennium/Takeda
- Novartis
- Bristol-Myers Squibb
- Gilead
- Genentech
- Roche
- AbbVie
- Acerta
- ECOG
- Infinity
- Mayo Clinic
- Pharmacyclics
- TG therapeutics
- Takeda
Ask authors/readers for more resources
The outcomes of patients with DLBCL and primary treatment failure (PTF) in the rituximab era are unclear. We analyzed 331 patients with PTF, defined as primary progression while on upfront chemoimmunotherapy (PP), residual disease at the end of upfront therapy (RD) or relapse <6 months from end of therapy (early relapse; ER). Median age was 58 years and response to salvage was 41.7%. Two-year OS was 18.5% in PP, 30.6% in RD and 45.5% in ER. The presence of PP, intermediate-high/high NCCN-IPI at time of PTF or MYC translocation predicted 2-year OS of 13.6% constituting ultra-high risk (UHR) features. Among the 132 patients who underwent autologous hematopoietic cell transplantation, 2-year OS was 74.3%, 59.6% and 10.7% for patients with 0,1 and 2-3 UHR features respectively. Patients with PTF and UHR features should be prioritized for clinical trials with newer agents and innovative cellular therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available